Treatment News : A Sustiva Trip? The HIV Med and LSD are Fellow Hallucinogens

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 11, 2013

A Sustiva Trip? The HIV Med and LSD are Fellow Hallucinogens

Known for its neuropsychiatric side effects, Sustiva (efavirenz) shares properties with LSD, according to a new research study. Potential side effects of Sustiva include depression, anxiety, sleep disturbances, difficulty concentrating, aggression, night terrors, hallucinations, paranoia, psychosis and delusions. In addition, anecdotal reports have suggested that people with HIV, as well as HIV-negative young people, crush the drug and smoke the powder in order to get high. In order to better understand the cause of the drug’s hallucinogenic effects, investigators conducted a study of how Sustiva interacts with various receptors in rat, rabbit and human cells; they also looked at the behavioral effects of the drugs when given to living rats and mice. Their findings were reported in Neuropsychopharmacology.

They found that Sustiva interacted with multiple receptors that are known sites governing the effects of drugs, including catecholamine and indoleamine transporters, and GABAA and 5-HT2A receptors. In particular, the serotonin 5-HT2A receptor, which is a main target for LSD and other related hallucinogens, appeared to be the dominant conduit for Sustiva’s drug-trip effects in rats.

To read a release on the study, click here.

To read the study abstract, click here.

Search: LSD, Sustiva, efavirenz, neuropsychiatric side effects, Neuropsychopharmacalogy, hallucinogenic.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.